Article
Rheumatology
Laura C. Coates, Enrique R. Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B. Campanholo, Jeffrey Chau, Lihi Eder, Daniel G. Fernandez-Avila, Oliver FitzGerald, Amit Garg, Dafna D. Gladman, Niti Goel, Philip S. Helliwell, M. Elaine Husni, Deepak R. Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip J. Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D. A. van der Windt, Arthur Kavanaugh
Summary: This article presents evidence-based treatment recommendations for Psoriatic Arthritis (PsA) medication selection, covering various clinical domains, related conditions and comorbidities. It provides important guidance and support for clinicians and individuals with PsA.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Article
Medicine, General & Internal
Yukari Okubo, Ann Chuo Tang, Sachie Inoue, Hitoe Torisu-Itakura, Mamitaro Ohtsuki
Summary: The study found that patients and physicians using biologics have higher treatment goals compared to non-biologics users, and biologic users also reported higher treatment satisfaction. Setting appropriate treatment goals that are shared between patients and their physicians may lead to better treatment outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Rebecca Persson, Myriam Cordey, Maria Paris, Susan Jick
Summary: This study compared the incidence rates of adverse events in patients receiving apremilast with those receiving other systemic treatments for psoriasis or psoriatic arthritis. The results showed that there were no new safety signals identified in the apremilast-exposed cohort. The incidence rates of adverse events were comparable between the apremilast and non-apremilast cohorts, indicating that the long-term safety of apremilast in real-world settings is similar to that reported in clinical trials.
Article
Dermatology
Joel M. Gelfand, April W. Armstrong, Stacie Bell, George L. Anesi, Andrew Blauvelt, Cassandra Calabrese, Erica D. Dommasch, Steven R. Feldman, Dafna Gladman, Leon Kircik, Mark Lebwohl, Vincent Lo Re, George Martin, Joseph F. Merola, Jose U. Scher, Sergio Schwartzman, James R. Treat, Abby S. Van Voorhees, Christoph T. Ellebrecht, Justine Fenner, Anthony Ocon, Maha N. Syed, Erica J. Weinstein, George Gondo, Sue Heydon, Samantha Koons, Christopher T. Ritchlin
Summary: This study updated guidance for managing psoriatic disease during the COVID-19 pandemic, with 22 original statements and 5 new recommendations. Results showed high consensus for 13 statements and moderate consensus for 14 statements. However, there are limitations in the evidence behind the guidance statements, with variable quality and quantity.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Medicine, Research & Experimental
April Armstrong, Emily Edson-Heredia, Baojin Zhu, Russel Burge, Stacie Bell, Jeffery J. Crowley, Stacy Smith
Summary: The survey results indicate that treatment preferences in patients with PsO may vary depending on factors such as age, severity, and gender. Different subgroups may have distinct treatment goals, highlighting the importance of individualized treatment decisions and optimizing patient outcomes.
ADVANCES IN THERAPY
(2022)
Article
Clinical Neurology
Ymkje Anna de Vries, Meredith G. Harris, Daniel Vigo, Wai Tat Chiu, Nancy A. Sampson, Ali Al-Hamzawi, Jordi Alonso, Laura H. Andrade, Corina Benjet, Ronny Bruffaerts, Brendan Bunting, Jose Miguel Caldas de Almeida, Giovanni de Girolamo, Silvia Florescu, Oye Gureje, Josep Maria Haro, Chiyi Hu, Elie G. Karam, Norito Kawakami, Viviane Kovess-Masfety, Sing Lee, Jacek Moskalewicz, Fernando Navarro-Mateu, Akin Ojagbemi, Jose Pusada Villa, Kate Scott, Yola Torres, Zahari Zarkov, Andrew Nierenberg, Ronald C. Kessler, Peter de Jonge
Summary: The study found that while a significant number of respondents reported receiving helpful treatment for specific phobias, only a small proportion persisted in seeking help from multiple professionals. Patient persistence in help-seeking after unsuccessful treatments could potentially increase the effectiveness of specific phobia treatment, but further research on barriers to help-seeking persistence is needed.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Dermatology
April Armstrong, David Amato, William Huster, Clement Ojeh, Abby S. Van Voorhees
Summary: The study found that ixekizumab, an interleukin 17 inhibitor, demonstrated high efficacy in treating patients with plaque psoriasis, achieving the treatment targets defined by NPF.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Dermatology
Asa Krantz, Juan Jesus Carrero, Yuanhang Yang, Lovisa Schalin, Josefin Lysell, Faizan Mazhar
Summary: Limited information exists regarding the treatment of patients with psoriasis/psoriatic arthritis in primary care. This study assessed treatment patterns, adherence, persistence, and compliance in newly diagnosed patients from 2012 to 2018 in Stockholm, Sweden. The findings revealed gaps in pharmacological care, including suboptimal adherence/persistence and inadequate laboratory monitoring.
ACTA DERMATO-VENEREOLOGICA
(2023)
Article
Dermatology
Riley K. Spencer, Joy Q. Jin, Kareem G. Elhage, Mitchell S. Davis, Marwa Hakimi, George Gondo, Wilson Liao, Tina Bhutani
Summary: This study aims to examine the association between sleep quantity and history of myocardial infarction in patients with psoriasis. The results showed that for each hour increase in average nightly sleep, patients with psoriasis have a 33% decrease in the odds of having a history of myocardial infarction.
DERMATOLOGY AND THERAPY
(2023)
Review
Rheumatology
Kristina Callis Duffin, Luis Daniel Mazzuoccolo, Maria Julia Cura, Maria Esposito, Anthony P. Fernandez, Paolo Gisondi, Alessandro Giunta, Tom Hillary, Stefano Piaserico, James A. Solomon, Joseph F. Merola
Summary: This study aimed to summarize and evaluate the current evidence on the efficacy of therapies for cutaneous psoriasis in patients with psoriatic arthritis. The findings suggest that several pharmacologic therapeutic classes have high-quality evidence demonstrating efficacy for cutaneous psoriasis in the psoriatic arthritis population.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Dermatology
Boni E. Elewski, John W. Baddley, Atul A. Deodhar, Marina Magrey, Phoebe A. Rich, Enrique R. Soriano, Jennifer Soung, Weibin Bao, Dorothy Keininger, Kwaku Marfo, Manmath Patekar, Abhishek Sharma, Abhijit Shete, Mark Gabriel Lebwohl
Summary: The study found that LTBI reported as an adverse event after secukinumab treatment was uncommon, supporting its use in chronic systemic inflammatory conditions.
Review
Dermatology
Kevin Yang, Allen S. W. Oak, Boni E. Elewski
Summary: Psoriasis is a common inflammatory skin disease with significant impact on quality of life. Biologic drugs like ustekinumab and guselkumab have shown efficacy in treating moderate-to-severe psoriasis and psoriatic arthritis with a favorable risk profile.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2021)
Review
Rheumatology
Conor Magee, Hannah Jethwa, Oliver M. FitzGerald, Deepak R. Jadon
Summary: The current study indicates that some biomarkers may be associated with treatment response in psoriatic disease, however, due to the diversity in research methods and outcomes, firm conclusions cannot be drawn and further validation is needed.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2021)
Review
Pharmacology & Pharmacy
Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. McInnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, Jose M. Carballido, Peter Hausermann, Claudio Calonder, Beate Vogel, Jean-Michel Rondeau, Gerard Bruin
Summary: Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases with varied symptoms and treatment responses. Secukinumab, a drug targeting IL-17A, has been used for over 6 years in the treatment of these diseases and has specific pharmacological properties.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Christine P. Lin, Joseph F. Merola, Elizabeth B. Wallace
Summary: Psoriasis and psoriatic arthritis are chronic inflammatory diseases that have a negative impact on quality of life. Understanding the disease mechanisms is crucial for selecting treatment options.
CURRENT OPINION IN PHARMACOLOGY
(2022)